Conference Reports for NATAP

Back

The 22st Conference of the Asian Pacific Association for the Study of the Liver APASL Feb 16-19, 2012 Taipei, Taiwan     HCV in China: HCV Viral and Host Genotypes Distribution among Han Ethnic Chinese in China - (02/28/12)   Estimating the incidence and prevalence of hepatitis C infection in Taiwan using backprojection methods - (02/28/12)   Early HBsAg decline as a predictor of HBsAg clearance in 'real life': results of the S-Collate cohort study in683 HBeAg-negative patients - (02/27/12)   S-Collate cohort study: on-treatment HBsAg level analysis in 'real-life' confirms prediction of response observed in NEPTUNE and phase III studies of peginterferon alfa-2a in HBeAg-positive patients - (02/27/12)   Five Years of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Associated with Sustained Viral Suppression and Significant Regression of Fibrosis and Cirrhosis - (02/27/12)   No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection - (02/27/12)   Low Baseline Hepatitis B Surface Antigen (HBsAg) Levels and HBV Genotypes B/C are Associated with Persistently Low HBsAg in HBeAg+ Patients Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/27/12)   Asians have Different Hepatitis B Surface Antigen (HBsAg) Kinetics than Non-Asians while Undergoing Treatment with Tenofovir Disoproxil Fumarate (TDF) or Adefovir (ADV) Followed by TDF up to 192 Weeks - (02/27/12)   Antiviral Activity of GS-9451, an HCV Specific NS3 Protease Inhibitor, in a Three-Day, Dose-Ranging, Monotherapy Study in Patients with Genotype 1 Hepatitis C Infection - (02/27/12)   Antiviral Activity and Characterization of Resistance in a Three Day Dose Ranging Study of GS-5885, a Novel HCV NS5A inhibitor - (02/27/12)   PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS - (02/27/12)   SAFETY AND EFFICACY OF PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED WITH PEGINTERFERON ALFA-2a (ALFA-2a) IN HCV-INFECTED PATIENTS (G1/2/3) WITH COMPENSATED CIRRHOSIS: EMERGE PHASE 2b EFFICACY AND SAFETY RESULTS THROUGH WEEK 12 - (02/27/12)   Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/25/12)   DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, COMBINED WITH PEGINTERFERON-ALFA-2a AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 OR 4 SUBJECTS: PHASE 2B AI444010 STUDY INTERIM WEEK 24 RESULTS - (02/25/12)   DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND THE NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1b-INFECTED NULL RESPONDERS OR PATIENTS INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN - (02/25/12)   DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2B AND RIBAVIRIN IN JAPANESE TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION - (02/25/12)   COMBINATION THERAPY OF TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH HCV GENOTYPE 1 INFECTION WITH DACLATASVIR (DCV; BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN - (02/25/12)   BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE-1 INFECTED ASIAN PATIENTS IN THE SPRINT-1, SPRINT-2, AND RESPOND-2 TRIALS - (02/23/12)   Response-guided danoprevir (DNV; RG7227) plus Peg-IFNα-2a and ribavirin (RBV) in ATLAS: High sustained virological response (SVR24) rates in treatment -naive hepatitis C virus (HCV) genotype 1 (G1) patients - (02/23/12)   INTERFERON (IFN)-FREE TREATMENT WITH ONCE-DAILY ALISPORIVIR (ALV) ACHIEVES AND MAINTAINS HIGH RATES OF UNDETECTABLE HCV RNA IN A GLOBAL POPULATION OF TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 (VITAL-1 STUDY) - (02/23/12)   Vertex QUAD Therapy Yielded 83-93% SVR with 12 weeks duration of therapy: VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAï VE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS - (02/22/12)   RETREATMENT WITH TELAPREVIR + PEGINTERFERON/RIBAVIRIN AFTER A SHORT EXPOSURE TO TELAPREVIR IN PHASE 1 STUDIES: INTERIM RESULTS FROM A PHASE 3B ROLLOVER TRIAL (C219) - (02/22/12)   IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE 3 REALIZE STUDY - (02/22/12)   EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE 3 STUDY - (02/22/12)   DRUG INTERACTION PROFILE OF TELAPREVIR - (02/22/12)   FOLLOW-UP OF SVR DURABILITY AND VIRAL RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR-BASED REGIMENS: INTERIM ANALYSIS OF THE EXTEND STUDY - (02/22/12)   SUSTAINED VIROLOGIC RESPONSE RATES AND VIRAL RESISTANCE PROFILES WERE SIMILAR IN PATIENTS TREATED WITH A TELAPREVIR-BASED REGIMEN REGARDLESS OF LIVER FIBROSIS STAGE - (02/22/12)   ALISPORIVIR (ALV) PLUS Peg-IFN/RBV (PR) HAS 100% SVR IN IL28B rs12979860 CC ALLELE AND SUPERIOR EFFICACY IN CHRONIC HEPATITIS C GENOTYPE (G) 1 TREATMENT-NAIVE PATIENTS COMPARED WITH PR: THE ESSENTIAL STUDY - (02/22/12)   Alisporivir, a Host-targeting Antiviral, in Combination with Peg-IFNα2a and Ribavirin Results in Superior SVR and No Viral Breakthrough in HCV Genotype 1 Treatment-naïve Patients of IL28B CC Genotype: Results from the Phase IIb ESSENTIAL Study - (02/22/12)   DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSESAFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS: "When examining this population of TVR-treated patients as a whole, there was a clear relationship between Week 4 response and SVR rates" - (02/22/12)